
June 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRM POTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE (GLP-1 RECEPTOR AGONIST)-INDUCED WEIGHT LOSS BY PRESERVING LEAN MASS
REGENERON PHARMACEUTICALS INC - 35% OF SEMAGLUTIDE-INDUCED WEIGHT LOSS DUE TO LEAN MASS LOSS
REGENERON PHARMACEUTICALS INC - COMBINATION THERAPY SPARES 50%-80% OF LEAN MASS LOST WITH SEMAGLUTIDE
REGENERON PHARMACEUTICALS INC - TRIPLET COMBINATION HAD HIGHER DISCONTINUATION RATE DUE TO ADVERSE EVENTS
REGENERON PHARMACEUTICALS INC: COMBINATION OF SEMAGLUTIDE WITH TREVOGRUMAB WAS GENERALLY WELL-TOLERATED